RegeneRx Biopharmaceuticals Inc logo

RGRX - RegeneRx Biopharmaceuticals Inc Share Price

$0.237 0.0  12.9%

Last Trade - 20/04/21

Micro Cap
Market Cap £20.0m
Enterprise Value £20.4m
Revenue £54.9k
Position in Universe 5977th / 6849
Unlock RGRX Revenue
Relative Strength (%)
1m -22.0%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -74.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.061 0.093 0.057 0.070 0.077 0.077 +4.8%
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, RegeneRxBiopharmaceuticals Inc revenues remained flat at $77K. Netloss applicable to common stockholders increased 2% to$1.5M. Revenues reflect market conditions. Higher net lossreflects Stock-based Compensation in SGA increase of 61% to$332K (expense), Interest Expense increase of 52% to $233K(expense), Interest income decrease of 66% to $4K (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


RGRX Revenue Unlock RGRX Revenue

Net Income

RGRX Net Income Unlock RGRX Revenue

Normalised EPS

RGRX Normalised EPS Unlock RGRX Revenue

PE Ratio Range

RGRX PE Ratio Range Unlock RGRX Revenue

Dividend Yield Range

RGRX Dividend Yield Range Unlock RGRX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
RGRX EPS Forecasts Unlock RGRX Revenue
Profile Summary

RegeneRx Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of a therapeutic peptide, Thymosin beta 4 (Tb4), for tissue and organ protection, repair and regeneration. The Company's segment is the development and marketing of product candidates based on Tb4, an amino acid peptide. The Company has formulated Tb4 into three product candidates in clinical development: RGN-259, RGN-352 and RGN-137. Tb4 is a synthetic copy of a naturally occurring 43-amino acid peptide that is originally isolated from bovine thymus glands. RGN-259 is its preservative-free eye drop formulation of Tb4. RGN-352 is an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration. RGN-137 is a topical gel for dermal wounds and reduction of scar tissue.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated May 13, 1982
Public Since December 23, 1986
No. of Shareholders: n/a
No. of Employees: 3
Sector Healthcare
Industry Pharmaceuticals
Exchange Pink Sheets on Nasdaq
Shares in Issue 133,546,788
Free Float (0.0%)
Eligible for
× ISAs
RGRX Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for RGRX
Upcoming Events for RGRX
Frequently Asked Questions for RegeneRx Biopharmaceuticals Inc
What is the RegeneRx Biopharmaceuticals Inc share price?

As of 20/04/21, shares in RegeneRx Biopharmaceuticals Inc are trading at $0.237, giving the company a market capitalisation of £20.0m. This share price information is delayed by 15 minutes.

How has the RegeneRx Biopharmaceuticals Inc share price performed this year?

Shares in RegeneRx Biopharmaceuticals Inc are currently trading at $0.237 and the price has moved by -29.91% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the RegeneRx Biopharmaceuticals Inc price has moved by -53.51% over the past year.

What are the analyst and broker recommendations for RegeneRx Biopharmaceuticals Inc?

Of the analysts with advisory recommendations for RegeneRx Biopharmaceuticals Inc, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for RegeneRx Biopharmaceuticals Inc is Not available. You can view the full broker recommendation list by unlocking its StockReport.

When will RegeneRx Biopharmaceuticals Inc next release its financial results?

RegeneRx Biopharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the RegeneRx Biopharmaceuticals Inc dividend yield?

RegeneRx Biopharmaceuticals Inc does not currently pay a dividend.

Does RegeneRx Biopharmaceuticals Inc pay a dividend?

RegeneRx Biopharmaceuticals Inc does not currently pay a dividend.

When does RegeneRx Biopharmaceuticals Inc next pay dividends?

RegeneRx Biopharmaceuticals Inc does not currently pay a dividend.

How do I buy RegeneRx Biopharmaceuticals Inc shares?

To buy shares in RegeneRx Biopharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of RegeneRx Biopharmaceuticals Inc?

Shares in RegeneRx Biopharmaceuticals Inc are currently trading at $0.237, giving the company a market capitalisation of £20.0m.

Where are RegeneRx Biopharmaceuticals Inc shares listed? Where are RegeneRx Biopharmaceuticals Inc shares listed?

Here are the trading details for RegeneRx Biopharmaceuticals Inc:

Country of listing: United States
Exchange: PNK
Ticker Symbol: RGRX
What kind of share is RegeneRx Biopharmaceuticals Inc?

Based on an overall assessment of its quality, value and momentum, RegeneRx Biopharmaceuticals Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a RegeneRx Biopharmaceuticals Inc share price forecast 2021?

We were not able to load any forecast data for RegeneRx Biopharmaceuticals Inc.

How can I tell whether the RegeneRx Biopharmaceuticals Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like RegeneRx Biopharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been -64.44%. At the current price of $0.237, shares in RegeneRx Biopharmaceuticals Inc are trading at -57.14% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the RegeneRx Biopharmaceuticals Inc PE Ratio?

We were not able to find PE ratio data for RegeneRx Biopharmaceuticals Inc.

Who are the key directors of RegeneRx Biopharmaceuticals Inc?

RegeneRx Biopharmaceuticals Inc's management team is headed by:

Allan Goldstein - CHM
Joseph McNay - IND
J. Finkelstein - PRE
Mauro Bove - IND
Raymond Elsey - IND
Alessandro Noseda - IND
Who are the major shareholders of RegeneRx Biopharmaceuticals Inc?

Here are the top five shareholders of RegeneRx Biopharmaceuticals Inc based on the size of their shareholding:

ESSETIFIN S.p.A. Corporation
Percentage owned: 26.2% (35.0m shares)
G-treeBNT Co., Ltd. Corporation
Percentage owned: 14.66% (19.6m shares)
McNay (Joseph C) Individual Investor
Percentage owned: 4.89% (6.52m shares)
Finkelstein (J J) Individual Investor
Percentage owned: 1.23% (1.64m shares)
Goldstein (Allan L) Individual Investor
Percentage owned: 1.13% (1.51m shares)
Similar to RGRX
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.